What is the history of Yenos Analytical's research?

Yenos Analytical LLC was founded by Dr. Anastassia Kanavarioti based on her research at UC Santa Cruz. The company received three NIH SBIR Phase I grants between 2018 and 2020 for early cancer detection research, providing federal validation of the scientific approach. The research progressed through four key publications: (1) 2020 — Proof of concept for the MinION/Yenos nanopore platform for DNA/RNA oligo detection (Scientific Reports); (2) 2022 — Femtomolar-level PCR-free quantification of miRNA cancer biomarkers in serum (bioRxiv preprint); (3) 2024 — Validation of the miR-21, miR-375, miR-141 panel with cancer and healthy samples (Non-Coding RNA); (4) 2025 — Comprehensive validation study reporting per-marker accuracy and zero data overlap (Int. J. Mol. Sci.). Three US patents plus international patents in eight countries protect the platform. OncuraKit is the commercial product built on this foundation.